US pharmaceutical group Eli Lilly has announced that the latest trial of its anti-obesity pill has met weight-loss targets, boosting its plans to seek approval for the drug as it fights for market dominance with rival Novo Nordisk.
Lilly said on Tuesday that its orforglipron pill reduced the body weight of people who were overweight and suffered from diabetes by 10.5 per cent on average. It noted that the side effects were similar to those for its injectable weight-loss drugs.
The results come after the market was disappointed earlier this month by the results of an orforglipron trial in people without diabetes: participants lost an average of 12.4 per cent of their body weight, at the lower end of expectations.
您已阅读26%（719字），剩余74%（2032字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。